Mehdi Sinaki examines the far-reaching implications of the DOJ’s recent marijuana rescheduling order in a new article for the Daily Journal. In the piece, Mehdi explores how the federal government’s narrow move to reclassify certain state-licensed medical cannabis products from Schedule I to Schedule III could deliver meaningful tax relief for licensed operators while simultaneously exposing cannabis businesses, clinicians, MSOs, and investors to heightened scrutiny under traditional healthcare laws, particularly in California. From corporate practice of medicine concerns and physician independence to referral relationships and evolving compliance obligations, Mehdi outlines why this regulatory shift represents far more than a tax story and why the next 12 to 18 months could reshape the legal landscape for the cannabis industry.
